Elranatamab

Elrexfio

44MG/1.1ML InjectionUnited StatesMarketedAuthorised 14 Aug 2023

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Elranatamab

Elrexfio

44MG/1.1ML InjectionUnited StatesMarketedAuthorised 14 Aug 2023

Open in the registerAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

ELREXFIO 40 mg/ml oplossing voor injectie

Netherlands · Oplossing voor injectie · Pfizer Europe MA EEIG

Elrexfio Solution for Injection 44 MG/1.1 MLSingapore · 44 mg/1.1 ml · injection, solution · Pfizer Private Limited

Elrexfio Solution for Injection 76 MG/1.9 MLSingapore · 76 mg/1.9 ml · injection, solution · Pfizer Private Limited

Documents

The official texts, at the regulator.

Register entryFDA

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions · Added 11 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Elranatamab
Strength: 44MG/1.1ML
Dosage form: Injection
Route: Subcutaneous
Register: United States (FDA)
Status: Marketed
Status in the register: Licensed / Rx
Authorised: 14 Aug 2023
Registration: BLA 761345
Marketing authorisation holder: Pfizer Inc.
Procedure: 351(a)
Supply: Rx